Repros Sees Renewed Confidence Print E-mail
By Brian Wilson, Contributor   
Friday, 07 September 2012 07:09
icon_marketmoverRepros Therapeutics (NASDAQ: RPRX) stock has rallied an impressive 60% in the last month on renewed confidence in the company's pipeline, which consists of the male fertility drug Androxal which inhibits estrogen receptors, and the female endometriosis and uterine fibroid treatment Proellex, which inhibits progesterone.
Read more...
 
Why is Carl Icahn Buying Large Blocks of Forest Laboratories? Print E-mail
By Brian Wilson, Contributor   
Thursday, 06 September 2012 07:04
icon_closerlookForest Laboratories (NYSE: FRX) is a ~$9 billion diversified pharmaceutical company that is heavily owned by investment managers. The company has been providing steady revenue growth for years and has an ever-expanding R&D budget, and has been attracting attention from the strength of the company's financial data.
Read more...
 
Diverse Pipeline And Multiple Catalysts Point To Buying Opportunity In NovaBay Pharmaceuticals Print E-mail
By Scott Matusow, Contributor   
Wednesday, 05 September 2012 07:21
icon_tradethesisTrading Biopharmaceuticals through a catalyst event can prove to be very rewarding for investors if the outcome from the company's catalyst is positive news.
Read more...
 
Will Alexza's Third Time Be the Charm? Print E-mail
By Brian Wilson   
Tuesday, 04 September 2012 03:36
icon_closerlookAlexza Pharmaceuticals (NASDAQ: ALXA) is a very small company by market capitalization (worth about $50.7 million based on current outstanding shares), and it seems to have a difficult time with its flagship drug ADASUVE (also known as staccato loxapine).
Read more...
 
Analyst Bets on Extraordinary Science and Clinical Data: Greg Wade Print E-mail
By M.E.Garza   
Friday, 31 August 2012 06:11
icon_expertbriefingManaging Director Greg Wade of Wedbush Securities doesn't use a cookie-cutter approach to picking biotechnology stocks. He directs investors to companies with strong science, well-executed clinical studies and data that points toward future success.
Read more...
 
Why Accumulating and Trading Shares of Medgenics Now May Not Be A Bad Idea Print E-mail
By M.E.Garza   
Wednesday, 29 August 2012 04:26
icon_PredictiveAnalysis On Tuesday afternoon, we tweeted to our followers that it might not be a bad idea to pick up some shares of Medgenics, Inc. (AMEX:MDGN) (AIM: MEDU, MEDG), particularly given the recent buzz about the firm's anticipated hepatitis pipeline development milestone. 
Read more...
 
Gilead’s Loss in the Pulmonary Hypertension Drug Race Puts Pluristem and Print E-mail
By Michael Morhamus   
Tuesday, 28 August 2012 09:29
icon_closerlookPulmonary arterial hypertension (PAH) is a chronic syndrome characterized by abnormally high pressure in arteries leading from the heart to the lungs that cause dizziness, fatigue, and shortness of breath.
Read more...
 
Chen Lin's Key to Huge Biotech Profits: Make It Personal Print E-mail
By George S. Mack of the Life Sciences Report   
Friday, 24 August 2012 05:12
icon_expertbriefingChen Lin is a well-known expert junior metals and

Error. Page cannot be displayed. Please contact your service provider for more details. (24)

energy investor, but he has found compelling reasons to diversify into biotechnology.
Read more...
 
Speculation for Opko Health Continues Print E-mail
By Brian Wilson   
Thursday, 23 August 2012 06:01
icon_insiderbuysOpko Health (NYSE: OPK) is an up-and-coming medical products company that is often the focus of speculation solely because of its CEO Dr. Phillip Frost, who is holding 128,490,000 shares of the company, which represents about 43% of the company's shares (not counting dilution).
Read more...
 
Another Opportunity To Benefit From Naked Short Trading Print E-mail
By M.E.Garza   
Wednesday, 22 August 2012 03:40
icon_tradethesisThe latest battle between longs and naked shorts may present traders another opportunity to benefit form being in the right trade at the right time.
Read more...
 
<< Start < Prev 51 52 53 54 55 Next > End >>

Page 51 of 55
BMR:1